vs

Side-by-side financial comparison of FRP HOLDINGS, INC. (FRPH) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.

Silence Therapeutics plc is the larger business by last-quarter revenue ($15.7M vs $10.9M, roughly 1.4× FRP HOLDINGS, INC.). FRP HOLDINGS, INC. runs the higher net margin — 1.3% vs -14.7%, a 16.0% gap on every dollar of revenue.

FRP Advisory is a business advisory firm based in the United Kingdom, providing restructuring, corporate finance, debt advisory, forensic accounting and financial advisory and is one of the UK’s largest specialists in the area of corporate restructuring.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

FRPH vs SLN — Head-to-Head

Bigger by revenue
SLN
SLN
1.4× larger
SLN
$15.7M
$10.9M
FRPH
Higher net margin
FRPH
FRPH
16.0% more per $
FRPH
1.3%
-14.7%
SLN

Income Statement — Q4 FY2025 vs Q1 FY2024

Metric
FRPH
FRPH
SLN
SLN
Revenue
$10.9M
$15.7M
Net Profit
$139.0K
$-2.3M
Gross Margin
82.2%
Operating Margin
15.4%
-35.6%
Net Margin
1.3%
-14.7%
Revenue YoY
3.6%
Net Profit YoY
-91.8%
EPS (diluted)
$0.03
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRPH
FRPH
SLN
SLN
Q4 25
$10.9M
Q3 25
$10.8M
Q2 25
$10.8M
Q1 25
$10.3M
Q4 24
$10.5M
Q3 24
$10.6M
Q2 24
$10.5M
Q1 24
$10.1M
$15.7M
Net Profit
FRPH
FRPH
SLN
SLN
Q4 25
$139.0K
Q3 25
$662.0K
Q2 25
$578.0K
Q1 25
$1.7M
Q4 24
$1.7M
Q3 24
$1.4M
Q2 24
$2.0M
Q1 24
$1.3M
$-2.3M
Gross Margin
FRPH
FRPH
SLN
SLN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
82.2%
Operating Margin
FRPH
FRPH
SLN
SLN
Q4 25
15.4%
Q3 25
12.6%
Q2 25
15.3%
Q1 25
22.6%
Q4 24
27.7%
Q3 24
29.0%
Q2 24
26.9%
Q1 24
28.4%
-35.6%
Net Margin
FRPH
FRPH
SLN
SLN
Q4 25
1.3%
Q3 25
6.1%
Q2 25
5.3%
Q1 25
16.6%
Q4 24
16.0%
Q3 24
12.8%
Q2 24
19.5%
Q1 24
12.8%
-14.7%
EPS (diluted)
FRPH
FRPH
SLN
SLN
Q4 25
$0.03
Q3 25
$0.03
Q2 25
$0.03
Q1 25
$0.09
Q4 24
$0.09
Q3 24
$0.07
Q2 24
$0.11
Q1 24
$0.07
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRPH
FRPH
SLN
SLN
Cash + ST InvestmentsLiquidity on hand
Total DebtLower is stronger
$192.6M
Stockholders' EquityBook value
$428.5M
$156.8M
Total Assets
$735.1M
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRPH
FRPH
SLN
SLN
Q4 25
Q3 25
$134.9M
Q2 25
$153.2M
Q1 25
$142.9M
Q4 24
$148.6M
Q3 24
$144.7M
Q2 24
$156.9M
Q1 24
$152.5M
Total Debt
FRPH
FRPH
SLN
SLN
Q4 25
$192.6M
Q3 25
$185.3M
Q2 25
$180.4M
Q1 25
$178.3M
Q4 24
$178.9M
Q3 24
$178.8M
Q2 24
$178.8M
Q1 24
$178.7M
Stockholders' Equity
FRPH
FRPH
SLN
SLN
Q4 25
$428.5M
Q3 25
$427.7M
Q2 25
$426.7M
Q1 25
$425.2M
Q4 24
$423.1M
Q3 24
$420.9M
Q2 24
$419.1M
Q1 24
$416.1M
$156.8M
Total Assets
FRPH
FRPH
SLN
SLN
Q4 25
$735.1M
Q3 25
$731.3M
Q2 25
$722.8M
Q1 25
$717.1M
Q4 24
$728.5M
Q3 24
$726.9M
Q2 24
$711.9M
Q1 24
$705.7M
Debt / Equity
FRPH
FRPH
SLN
SLN
Q4 25
0.45×
Q3 25
0.43×
Q2 25
0.42×
Q1 25
0.42×
Q4 24
0.42×
Q3 24
0.42×
Q2 24
0.43×
Q1 24
0.43×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRPH
FRPH
SLN
SLN
Operating Cash FlowLast quarter
$29.7M
$-9.1M
Free Cash FlowOCF − Capex
$-21.5M
FCF MarginFCF / Revenue
-196.6%
Capex IntensityCapex / Revenue
468.5%
0.0%
Cash ConversionOCF / Net Profit
213.50×
TTM Free Cash FlowTrailing 4 quarters
$-34.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRPH
FRPH
SLN
SLN
Q4 25
$29.7M
Q3 25
$8.1M
Q2 25
$8.7M
Q1 25
$4.5M
Q4 24
$29.0M
Q3 24
$6.3M
Q2 24
$12.2M
Q1 24
$2.9M
$-9.1M
Free Cash Flow
FRPH
FRPH
SLN
SLN
Q4 25
$-21.5M
Q3 25
$-16.9M
Q2 25
$2.6M
Q1 25
$1.4M
Q4 24
$-22.2M
Q3 24
$-28.2M
Q2 24
$5.9M
Q1 24
$-3.3M
FCF Margin
FRPH
FRPH
SLN
SLN
Q4 25
-196.6%
Q3 25
-157.0%
Q2 25
24.0%
Q1 25
13.6%
Q4 24
-210.9%
Q3 24
-265.7%
Q2 24
56.0%
Q1 24
-32.6%
Capex Intensity
FRPH
FRPH
SLN
SLN
Q4 25
468.5%
Q3 25
232.0%
Q2 25
55.9%
Q1 25
30.1%
Q4 24
486.1%
Q3 24
325.1%
Q2 24
60.3%
Q1 24
61.2%
0.0%
Cash Conversion
FRPH
FRPH
SLN
SLN
Q4 25
213.50×
Q3 25
12.21×
Q2 25
15.00×
Q1 25
2.63×
Q4 24
17.18×
Q3 24
4.65×
Q2 24
5.96×
Q1 24
2.23×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRPH
FRPH

Other$5.6M51%
Multifamily Segment$5.3M49%

SLN
SLN

Segment breakdown not available.

Related Comparisons